GlassScriptPhysician profile
Syed A Karim
NPI 1366698060
$17,168.64
in general payments reported to CMS, 2019-2025
39 companies · $2,626 in 2025
The $2,626 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,051 · 2020: $1,556 · 2021: $2,529 · 2022: $2,283 · 2023: $3,547 · 2024: $3,576 · 2025: $2,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,749.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,606.79 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $2,208.36 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,448.33 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $1,323.09 | 2019-2022 | |
| Tris Pharma INC | $1,151.32 | 2019-2025 | Dyanavel Xr, Onyda Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,106.30 | 2021-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $829.07 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $736.63 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $716.62 | 2019-2025 | Trintellix |
| Alkermes, INC. | $620.76 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $579.00 | 2019-2025 | Fanapt, Hetlioz |
| Corium, LLC | $516.68 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $435.47 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $386.89 | 2021-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $338.80 | 2021-2024 | Qelbree, Qelbree |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Karim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.